1. Meaning 

The Clinical Neurotechnology Governance Doctrine is a proposed legal and regulatory framework for ensuring that technologies which measure, stimulate, interpret, or modify human brain activity are developed and used safely, ethically, transparently, and accountably in clinical settings.

Neurotechnology includes brain–computer interfaces (BCIs), deep-brain stimulation (DBS), electroencephalography (EEG)-based diagnostic systems, neuroprosthetics, neural implants, and software that interprets neural signals using artificial intelligence.

The doctrine seeks to answer a central legal question:

Who should be responsible when a neurotechnology system influences a patient's brain activity, clinical treatment, mental privacy, or decision-making capacity?

It is important to clarify that this is an analytical legal doctrine, not a universally established doctrine with one settled definition or a single leading judicial precedent. Its principles are derived from established areas of law, including medical negligence, informed consent, constitutional rights, product liability, data protection, medical-device regulation, and human-rights law.

Core objectives

Patient safety: Prevent injury caused by defective neural devices, inappropriate stimulation, or unreliable diagnostic algorithms.

Autonomy and informed consent: Ensure patients understand the purpose, risks, alternatives, and limitations of neurotechnology.

Mental privacy: Protect neural data and sensitive inferences about a person's cognitive or emotional state.

Clinical accountability: Identify the respective duties of physicians, hospitals, device manufacturers, software developers, and regulators.

Fairness and access: Prevent discriminatory treatment and unjustified exclusion from clinical services.

Continuing oversight: Require monitoring, incident reporting, and corrective action after a device enters clinical use.

2. Scope of the doctrine

Estimulação Cerebral Profunda (DBS) na Doença de Parkinson

A. Invasive neurotechnology

Examples include deep-brain stimulation implants, implanted electrodes, and invasive brain–computer interfaces. Governance must address surgical risks, device malfunction, stimulation-related adverse effects, cybersecurity, maintenance, and removal or replacement.

EEG tests for epilepsy - Epilepsy Action

B. Non-invasive neurotechnology

EEG systems, neurofeedback, and other external brain-monitoring devices raise questions about diagnostic accuracy, informed consent, data retention, and the clinical validity of interpretations.

AI-Powered Co-pilot Offers New Autonomy for People with Paralysis | Carle Illinois College of Medicine | Illinois

C. AI-assisted neural systems

Systems that decode neural signals or recommend clinical interventions require validation, human oversight, traceability, and safeguards against automation bias.

The applicable legal obligations depend on the technology's intended purpose, the clinical context, the patient's circumstances, and the jurisdiction.

3. Essential principles of the governance doctrine

A. Informed consent and clinical autonomy

A patient should receive meaningful information about the proposed neurotechnology, its expected benefits, material risks, alternatives, uncertainties, and possible long-term effects.

Consent to implantation should not automatically be treated as consent to every subsequent software update, neural-data analysis, research use, or secondary commercial use. Separate consent or another valid legal basis may be necessary, depending on the activity.

Where the patient has impaired decision-making capacity, clinicians must follow the applicable rules governing capacity, supported decision-making, representatives, and emergency treatment.

B. Safety, efficacy, and scientific validation

Before clinical deployment, manufacturers and healthcare institutions should establish that the device is sufficiently safe and effective for its intended use.

Governance should include:

Appropriate preclinical testing and clinical evaluation.

Verification of device performance across relevant patient populations.

Assessment of stimulation-related risks and foreseeable malfunctions.

Controlled software updates and cybersecurity testing.

Monitoring of adverse events and long-term outcomes.

Procedures for device recalls, corrective action, and patient notification.

A system that works for one neurological condition should not automatically be assumed suitable for another.

C. Neural-data protection and mental privacy

Neural signals and the inferences derived from them may reveal highly sensitive information. A governance framework should therefore distinguish among:

Raw neural signals collected by a device.

Clinically interpreted neurological information.

Algorithmic inferences about cognitive or emotional states.

Data retained for research, commercial analytics, or product development.

Each category can pose different risks. Even when data are lawfully collected, their later use may exceed the patient's reasonable expectations or the originally disclosed purpose.

The 2025 scholarly review of US neurotechnology governance identifies privacy, safety, autonomy, transparency, and accountability as major areas requiring stronger oversight.

PMC+1

D. Human oversight and algorithmic accountability

A physician should not accept an AI-generated neurological diagnosis or treatment recommendation merely because it comes from a sophisticated system.

A sound governance model requires:

Clinical review of consequential automated recommendations.

Documentation of reasons for accepting or rejecting them.

Procedures for identifying unreliable outputs and model drift.

Clear allocation of responsibility among clinicians, hospitals, and vendors.

An accessible process for patients to question consequential decisions.

Human oversight must be meaningful. A clinician who cannot understand the system's limitations or override its recommendation may not provide effective oversight.

E. Equity, dignity, and non-discrimination

Clinical neurotechnology must not be used to unjustifiably disadvantage patients because of neurological disability, socioeconomic status, or other protected characteristics.

Governance should also address whether a patient can refuse an optional enhancement without losing access to ordinary medical treatment, employment opportunities, or essential services.

F. Post-treatment responsibility

Governance does not end when an implant is installed or a patient leaves the hospital. Responsibility may extend to maintenance, battery replacement, software support, remote monitoring, device withdrawal, and continuity of care.

The relevant duties depend on who controls each stage and what risks were reasonably foreseeable.

4. Indian statutory and constitutional framework

India does not currently have one comprehensive statute devoted exclusively to clinical neurotechnology. Its governance must be assessed through existing constitutional, medical, data-protection, and consumer-law principles.

The precise application of these laws depends on the device, the use of the data, the parties involved, and the relevant statutory provisions. The DPDP Act should not be described as a standalone neural-data law, and not every neurotechnology product will fall into the same regulatory category.

5. Leading case laws and their application

The following judgments do not all concern therapeutic neurotechnology directly. They establish legal principles that can be applied to disputes involving neural implants, brain stimulation, neural-data processing, and clinical decision-making.

Case 1: Justice K.S. Puttaswamy (Retd.) v. Union of India (2017) 10 SCC 1

Constitutional foundation

Court: Supreme Court of India
Decision: 24 August 2017.

Indian Kanoon+1

Facts and legal issue: The case concerned whether the right to privacy is protected as a fundamental right under the Indian Constitution.

Judgment: The nine-judge Constitution Bench unanimously recognised privacy as a constitutionally protected fundamental right, including under Article 21 and the freedoms in Part III.

Application to clinical neurotechnology: This judgment provides a strong foundation for protecting identifiable neural data, mental privacy, bodily autonomy, and sensitive neurological information.

For example, a hospital that proposes to use neural recordings for an unrelated commercial purpose may need to justify the processing under applicable data-protection law and respect constitutional rights where State action is involved.

The judgment's legality, legitimate-aim, and proportionality framework is particularly important when the State proposes compulsory neural monitoring.

Legal significance: The case supports privacy-based challenges to unjustified neurotechnology use. It does not, however, expressly establish a separate constitutional right called the right to neural privacy.

Case 2: Selvi v. State of Karnataka (2010) 7 SCC 263

Mental autonomy and non-compulsion

Court: Supreme Court of India
Decision: 5 May 2010.

API Sci+1

Facts: The case challenged the involuntary use of narcoanalysis, polygraph examinations, and Brain Electrical Activation Profile (BEAP) testing during criminal investigations.

Judgment: The Supreme Court held that involuntary administration of the techniques in question violated Article 20(3)'s protection against compelled self-incrimination and implicated personal liberty under Article 21.

Application to neurotechnology: The case is highly relevant when brain-related measurements are used to attempt to extract information from a person without valid consent, especially during interrogation.

It supports the proposition that technological access to a person's brain does not automatically remove constitutional protections merely because the method is scientific.

Important limitation: Selvi did not prohibit all voluntary clinical EEG, neuroimaging, or brain-stimulation procedures. Its holdings must be applied to the specific legal context rather than extended indiscriminately to therapeutic neurotechnology.

Case 3: Samira Kohli v. Dr. Prabha Manchanda (2008) 2 SCC 1

Court: Supreme Court of India
Decision: 16 January 2008.

Indian Kanoon+1

Facts: A patient consented to a diagnostic procedure, but the doctor performed additional major surgery without obtaining the patient's specific consent.

Judgment: The Supreme Court explained that valid medical consent must be voluntary, given by a competent person, and based on adequate information. Consent to one procedure does not ordinarily authorise a different procedure. A narrow exception exists where an additional procedure is necessary to save life or preserve health and it would be unreasonable to delay it.

Application to neurotechnology: A patient who agrees to a neural implant for treatment of a neurological disorder has not necessarily agreed to:

Additional experimental stimulation.

Non-essential alterations to the treatment plan.

Unrelated research use of neural recordings.

Disclosure of neural data for commercial profiling.

The precise consent requirements will depend on the intervention and applicable law.

Legal significance: This is one of the strongest Indian authorities for patient autonomy in clinical neurotechnology governance.

Case 4: Maneka Gandhi v. Union of India (1978) 1 SCC 248

Court: Supreme Court of India

Legal principle: State action affecting personal liberty must comply with a procedure that is fair, just, and reasonable.

Application: If a public hospital or government authority imposes compulsory neural monitoring, it must be assessed against applicable constitutional safeguards. A policy cannot be justified solely by administrative convenience or technological efficiency.

This principle complements Puttaswamy when evaluating the lawfulness and fairness of intrusive neurotechnology practices.

Case 5: Canterbury v. Spence, 464 F.2d 772 (D.C. Cir. 1972)

Court: United States Court of Appeals for the District of Columbia Circuit

Legal principle: The decision is an influential authority on a physician's duty to disclose material treatment risks so that a patient can make an informed choice.

Application: In a neurotechnology context, disclosure may need to address material risks such as infection, neurological injury, device malfunction, stimulation-related behavioural effects, uncertainty about long-term outcomes, and available alternatives.

Jurisdictional limitation: This is a US appellate decision, not binding authority in India. Its relevance is comparative and persuasive, subject to Indian law.

Case 6: Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993)

Court: Supreme Court of the United States

Legal principle: Under the US Federal Rules of Evidence framework, trial judges assess whether expert scientific evidence is relevant and reliable.

Application: If a litigant relies on neural-signal analysis to claim that a patient was conscious, incapable of making decisions, experiencing a particular cognitive state, or likely to suffer a specific outcome, the scientific reliability of that evidence matters.

Courts should distinguish between a validated clinical finding and a probabilistic algorithmic inference that has not been adequately tested.

Jurisdictional limitation: Daubert governs US federal evidence law; it does not automatically determine admissibility in Indian courts.

6. Liability and accountability under the doctrine

A central function of clinical neurotechnology governance is to determine which actor bears responsibility when a patient suffers harm.

These are potential grounds of responsibility, not automatic findings of liability. The applicable cause of action, evidence of breach, causation, available defences, and recoverable damages must be established in each case.

Illustrative hypothetical

Suppose a hospital implants a brain-stimulation device to treat a patient's movement disorder. Following a software update, the device malfunctions and causes serious adverse effects.

The governance analysis would ask:

Was the update appropriately tested and authorised?

Did the manufacturer disclose known risks?

Did the hospital follow applicable update and monitoring protocols?

Was the patient informed about material risks and alternatives?

Did the parties respond appropriately after detecting the malfunction?

Did a particular act or omission cause the patient's injury?

Depending on the evidence, more than one party could be responsible.

7. A proposed governance framework for India

A practical version of the doctrine could be implemented through the following seven safeguards.

1. Risk-based legal classification

Classify devices according to invasiveness, clinical purpose, potential neurological harm, autonomy risks, and the sensitivity of data processed.

2. Pre-market assessment

Require appropriate safety, performance, and clinical evidence before authorising high-risk medical neurotechnology.

3. Specific informed consent

Explain material risks, alternatives, data practices, and relevant uncertainties. Establish procedures for withdrawal of consent where applicable.

4. Neural-data safeguards

Implement purpose limitation, appropriate access controls, security measures, retention policies, and safeguards against unauthorised secondary use.

5. Clinical oversight

Preserve meaningful professional judgment and establish review procedures for consequential AI recommendations and automated device adjustments.

6. Post-market surveillance

Require appropriate incident reporting, adverse-event investigation, corrective action, and continued evaluation of device performance.

7. Effective remedies

Provide accessible complaint mechanisms, independent investigation where appropriate, and compensation or other remedies when liability is established.

This is a proposed governance model rather than a description of seven existing statutory duties applicable identically to every device.

8. International and emerging governance developments

Neurotechnology regulation is developing unevenly across jurisdictions.

United States: Existing medical-device, privacy, research, and consumer-protection laws address some risks, while neural-data-specific protections have emerged in certain states. A 2025 policy review describes the federal governance landscape as fragmented and substantially dependent on nonbinding guidance.

PMC+1

Chile: Constitutional and legislative developments have made neuro-rights a significant subject of legal debate. These developments offer comparative material for discussions of mental integrity and cognitive liberty.

European Union: The GDPR may protect identifiable neural information under applicable personal-data and special-category rules. Medical-device regulation may also apply, depending on the product and intended use.

UNESCO: Its Recommendation on the Ethics of Neurotechnology, adopted in November 2025, offers an international normative framework. A recommendation is not, by itself, a binding treaty.

Live Law+1

India: Puttaswamy and Selvi provide important constitutional foundations, while medical-device and data-protection rules may address particular aspects of clinical use. A dedicated, comprehensive neurotechnology statute should not be assumed to exist.

9. Critical legal issues and unresolved questions

Several questions remain especially important for legislators, courts, hospitals, and researchers.

First, who controls neural data? Ownership is not necessarily the best legal model. Rights to access, use, disclose, delete, or retain data may be governed by different statutory and contractual rules.

Second, how should responsibility be allocated when AI causes harm? A manufacturer may design the software, a hospital may configure it, and a clinician may make the final treatment decision. Courts must examine the conduct and duties of each party rather than presume that only one actor is responsible.

Third, how should cognitive liberty be protected? Existing privacy and bodily-integrity principles can address many concerns, but the precise legal boundaries of a distinct right to cognitive liberty remain unsettled in India.

Fourth, how should innovation be balanced against precaution? Excessively weak oversight can expose patients to avoidable harm; excessively restrictive rules can delay beneficial treatments for conditions such as Parkinson's disease, epilepsy, and paralysis.

Fifth, what happens when a patient becomes dependent on an implant? A governance framework must consider continuity of care, vendor insolvency, discontinued software support, device replacement, and safe withdrawal.

10. Conclusion

The Clinical Neurotechnology Governance Doctrine can be understood as a proposed framework built around safety, informed consent, mental privacy, clinical accountability, scientific reliability, and effective legal remedies.

For Indian law, the most important foundational precedents are:

Justice K.S. Puttaswamy v. Union of India (2017) — constitutional privacy and autonomy.

Selvi v. State of Karnataka (2010) — protection against involuntary scientific interrogation and compelled self-incrimination.

Samira Kohli v. Dr. Prabha Manchanda (2008) — informed consent and the limits of authorisation for medical procedures.

Maneka Gandhi v. Union of India (1978) — fair, just, and reasonable procedure affecting personal liberty.

Together, these decisions support important safeguards for clinical neurotechnology, but none should be misrepresented as having established the entire proposed doctrine.

The long-term objective is to ensure that technological access to the human nervous system does not diminish human dignity, patient autonomy, or the accountability of those who design and deploy these systems.

For further legal research, a useful next step would be to develop a case-law matrix linking each governance principle to specific Indian statutory provisions, judicial holdings, and unresolved legal questions.